Developing Breakthrough Therapies for Rare Inflammatory Diseases

Resunab™ is a first in class, oral anti-inflammatory drug that acts to resolve inflammation entering Phase 2 clinical trials pending FDA approval

Learn more

Developing Breakthrough Therapies for Rare Inflammatory Diseases

Resunab™ is a first in class, oral anti-inflammatory drug that acts to resolve inflammation entering Phase 2 clinical trials pending FDA approval

Learn more

Developing Breakthrough Therapies for Rare Inflammatory Diseases

Resunab™ is a first in class, oral anti-inflammatory drug that acts to resolve inflammation entering Phase 2 clinical trials pending FDA approval

Learn more

Developing Breakthrough Therapies for Rare Inflammatory Diseases

Resunab™ is a first in class, oral anti-inflammatory drug that acts to resolve inflammation entering Phase 2 clinical trials pending FDA approval

Learn more
About

About

Corbus Pharmaceuticals is a clinical stage biopharmaceutical company focusing on rare, life-threatening, chronic inflammatory diseases. Learn More
Technology

Technology

Our technology revolves around the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases.

Learn More
Indications

Indications

Corbus Pharmaceuticals is dedicated to developing therapeutics that help to better the lives of patients with rare chronic inflammatory conditions.

Learn More

Pipeline

Corbus Pharmaceuticals is developing Resunab™ for the treatment of chronic ("orphan") inflammatory diseases in which inflammation leads to chronic fibrosis.

View Details
PreClinical Phase 1 Safety Phase 2a Study Phase 2b/phase 3 pivotal study
Cystic Fibrosis
Pre-Clinical Phase completed
Phase 1 completed
Ready to Enter Phase 2
Phase 2B not started
Diffuse Scleroderma
Pre-Clinical Phase completed
Phase 1 completed
In Phase 2
Phase 2B not started

Investor Information View Investor Relations

CRBP Loading...
NASDAQ Loading...
Volume Loading...
Market Cap Loading...
Change Loading...

Sign up for Email Alerts

Receive breaking news first!

Investor Presentation